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DCE among Dutch health care professionals (policymakers, HTA specialists, advanced 
HTA students). In 27 choice sets, we asked respondents to elect reimbursement of one 
of two different health care interventions, which represented unlabeled, curative treat-
ments. Both treatments were incrementally compared to usual care. The results of the 
interventions were normal outputs of HTA studies with a societal perspective. Results 
were analysed using a multinomial logistic regression model. Upon completion of the 
questionnaire we discussed the exercise with policymakers. RESULTS: Severity of 
disease, costs per QALY gained, individual health gain, and the budget impact were 
the most decisive decision criteria. A program targeting more severe diseases increased 
the probability of reimbursement dramatically. Uncertainty related to the cost-effec-
tiveness ratio was also important. Respondents preferred health gains that include 
quality of life improvements over extension of life without improved quality of life. 
Savings in productivity costs were not crucial in decision making, although these are 
to be included in Dutch reimbursement dossiers for new drugs. Regarding sub groups, 
we found that policymakers attached relatively more weight to disease severity than 
others but less to uncertainty. The DCE results indicated a willingness to pay of about 
a93,000 for a QALY. This meshes nicely with the recommendations of the Dutch 
Health Care Council. CONCLUSIONS: Dutch policymakers seem to have reasonably 
well articulated preferences: six of seven attributes were signiﬁcant. Disease severity, 
budget impact, and cost-effectiveness were very important. The results are comparable 
to international studies, but reveal a larger set of important decision criteria.
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OBJECTIVES: In contrast to the US, several European countries have health technol-
ogy assessment programs (HTA) for drugs, many of which assess cost-effectiveness. 
However, restricting access to pharmaceuticals is controversial, particularly for life-
threatening diseases. Therefore the objective of this study was to assess whether eco-
nomic evaluation as part of HTA restricts access to anticancer drugs. METHODS: 
We undertook a systematic comparison of US and UK coverage decisions on anticancer 
drugs taken by the US Centers for Medicare and Medicaid (CMS), the Veterans’ Affairs 
(VA), the Regence Group (US), the National Institute for Health and Clinical 
Excellence (NICE) (UK), and the Scottish Medicines Consortium (SMC) (UK). We 
noted the timing and outcome of coverage decisions made for all anticancer drugs 
approved by the Food and Drug Administration (FDA) between 2004 and 2008. 
RESULTS: Since 2004, the FDA has approved 51 anticancer drugs, of which 39 have 
been approved by the European Medicines Agency (EMEA). On average, the FDA 
licensed these drugs 127 days earlier than EMEA. The CMS and the VA covered 
all 51 drugs from the FDA license date. The Regence group also covered all 51 
drugs, although coverage decisions that considered cost-effectiveness sometimes took 
longer. Relative to the EMEA license date, coverage decisions for anticancer drugs by 
NICE averaged 774 days (SMC: 231 days). In the US, most drugs were available 
without clinical restriction, but NICE made positive coverage decisions for just 33% 
of licensed drugs (SMC: 51%). However, US patients face substantial copayments, 
whereas drugs are free for UK cancer patients. CONCLUSIONS: The use of economic 
evaluation does lead to more restrictions on the use of anticancer drugs. However, 
the major difference between the UK and US is not whether there are restrictions on 
access to anticancer drugs, but how these are applied and who bears the decision-
making burden.
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BACKGROUND: HTA has become the key tool to control market access for new 
technologies in Europe. This development has been mirrored in Germany through 
institutions such as DIMDI and, later, IQWiG at federal level, paralleled by similar 
tools at sickfund level. Furthermore, bilateral market access agreements appear to 
bloom. OBJECTIVES: To explore the foundation and trends of future health care 
decision-making in Germany. To formulate recommendations to manufacturers 
seeking market access for new technologies in Germany with respect to a number of 
key launch parameters. METHODS: We reviewed the development of allocative deci-
sion-making in Germany with particular attention to IQWiG (methods, international 
collaboration, decisions to date, impact). Furthermore, the role of other routes was 
examined (EVITA, rebate contracts, risk-sharing). RESULTS: IQWiG assessments 
have had a crucial impact on some products, e.g. clopidogrel and the fast-acting insulin 
analogues, and other manufacturers can learn from these decisions. While IQWiG will 
most likely cooperate with NICE and HAS on a number of issues such as evidence 
synthesis, a harmonized set of methods, leave alone decisions, cannot be expected in 
the near future. The future signiﬁcance of other access routes still needs to be deter-
mined. CONCLUSIONS: Manufacturers must be prepared for IQWiG assessments 
to be used for pricing purposes. Evidence must stem from randomized controlled 
trials wherever possible. Cost-effectiveness analysis will remain a second step of the 
appraisal, to which a new technology will only be admitted after having overcome a 
stand-alone effectiveness assessment. Neither QALYs nor a cost-per-QALY threshold 
will be used for decision-making. Germany will continue to grant high rewards to 
innovation, but careful thought must be given by manufacturers on how to present 
the added value of such innovations—be it via the IQWiG, a potential EVITA, or a 
direct contracting route.
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OBJECTIVE: Elderly (65y) are steadily growing, but this population segment is also 
the one in whom mortality, morbidity and health care costs increase sharply with age 
as a result of co-morbidity and greater frailty. This project intends to document the 
implications of using different modelling approaches on the beneﬁt evaluation of a 
public health intervention in elderly. METHODS: We designed a mathematical model 
to simulate the effect of a hypothetical public health intervention aiming at reducing 
mortality in the 65 y. The simulation is run on an elderly population of 1,000,000 
individuals (age weighted average of 75.66 y). The impact of the intervention is com-
pared between a cohort model (i.e., average parameters applied to the 75.66 year- old 
elderly cohort) and a population model (i.e., age-speciﬁc parameters applied to the 
entire elderly population). Life-expectancy gains (LEG) from both approaches were 
computed between intervention and no-intervention. Various scenarios were com-
pared through a range of different mathematical speciﬁcations of age-speciﬁc inter-
vention coverage and mortality reduction. RESULTS: In the cohort approach, life 
expectancies were respectively 11.38 and 11.48 years between no-intervention and 
intervention, i.e. a LEG of 0.10 y for the 75.66 y-old elderly cohort. In the population 
approach, age-speciﬁc life expectancies averaged 11.51 and 12.19 y between no-
 intervention and intervention, respectively. This translated into a weighted average 
LEG of 0.52 y, i.e. a gain 5-times higher than in the cohort approach. This result was 
conﬁrmed in various scenarios. CONCLUSION: Population modelling, whilst being 
potentially more data-hungry and mathematically demanding, allows for more com-
prehensive consideration of age-speciﬁc parameters in the decision-making process. 
This approach has the potential to better capture the whole beneﬁt of a population-
wide intervention which is particularly insightful in the elderly for whom mortality, 
disability and costs of health care are even more age-sensitive.
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OBJECTIVES: Cost-effectiveness analyses of behavioural health interventions typi-
cally use a dichotomous outcome criterion (success or failure). However, achieving 
behavioural change is a complex process in which several steps towards behavioural 
change are taken. Delayed behavioural effects may occur after an intervention or 
follow-up period ends, which can lead to underestimation of these interventions. As 
extending the follow-up period is often impeded by practical and ﬁnancial limitations, 
intermediate outcomes of behavioural change can be modelled into the cost-
 effectiveness ratio. The aim of this study is to model intermediate cognitive outcomes 
into a cost-effectiveness model of a behavioural intervention, comparing an intensive 
smoking cessation program (SST) with a less intensive smoking cessation program 
(LMIS) for COPD outpatients. METHODS: The cost-effectiveness analysis of an 
existing dataset was replicated by modelling the stages of change of the Transtheoreti-
cal Model of behavioural change. This stage-oriented model describes the readiness 
to change in qualitatively different, discrete stages; the ‘stages of change’. Costs were 
adjusted for the different stages of change participants were in. Probabilities to predict 
future behavioural change were obtained from the dataset and literature. Finally, a 
sensitivity analysis was performed. RESULTS: In the ﬁrst 12 months, the SST domi-
nated the LMIS in approximately 50% of the cases. By modelling the intermediate 
cognitive determinants to a future second year of follow-up, the SST dominated the 
LMIS in approximately 75% of all cases. CONCLUSIONS: This study showed that 
modelling of future behavioural change in cost-effectiveness analysis of a behavioural 
intervention led to a more favourable result. Further research should focus on collect-
ing longitudinal data of the cognitive determinants for different populations and 
outcome measures to be able to make a valid prediction of future behavioural change. 
Ultimately, this could have important consequences for health policy development in 
general and the adoption of behavioural interventions in particular.
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OBJECTIVES: Comparison of the results of a decision analytic model developed in 
Microsoft Ofﬁce Excel® 2007 versus an implementation of the same model in R 
version 2.8.1 (www.R-project.org). The aim was to identify any difference in the per-
formance and validity between models implemented with the two software packages 
in terms of incremental cost-effectiveness ratio (ICER) estimates and probabilistic 
